Can dehydroepiandosterone prevent chemotherapy-related damage? Investigation of protective effects of dehydroepiandosterone against paclitaxel-induced toxicity damage in rat ovaries

Year 2020, Volume: 37 Issue: 3, 97 - 103, 30.04.2020

Önder Sakin , Muhammet Ali Oruç , Ali Doğukan Anğın , Yasemin Alan , Mustafa Gökkaya , Hasan Sağdıç , Emre Mat , Kayhan Başak , Murat Alan

https://izlik.org/JA95RS85UL

Abstract

Our aim is to evaluate whether dehydroepiandosterone has a protective effect on paclitaxel-induced ovarian damage. Group 1 (the control group): No treatment was administered. Intact ovarian tissue was removed and blood samples were taken for anti-mullerian hormone (AMH) test. Group 2 (the paclitaxel group): Rats received paclitaxel intraperitoneally at a single dose of 7.5 mg/kg. Group 3 (the paclitaxel + DHEA group): Rats received paclitaxel intraperitoneally at a single dose of 7.5 mg / kg at baseline and DHEA subcutaneously for 10 days at a dose of 60 mg / kg daily. Rats in groups 2 and 3 were sacrificed at the end of 10 days, ovarian tissues were removed and blood samples were taken for AMH test. The edema score was higher in the paclitaxel+DHEA group than in the normal group. Vasculary congestion score was higher in the paclitaxel and paclitaxel+DHEA groups than in the normal group. Cellular degeneration score was higher in paclitaxel group than normal group. Total score was higher in the paclitaxel and paclitaxel+DHEA groups than in the normal group. In the paclitaxel group, the number of tertiary follicles and ovarian volume were lower than in the normal group. Primordial follicles, secondary follicles, tertiary follicles, AMH level and ovarian volume of paclitaxel+DHEA group were lower than normal group. In conclusion DHEA was found to increase damage in paclitaxel-treated rats, leading to a decrease in follicle counts and AMH.

Keywords

Paclitaxel , dehydroepiandrosterone , anti-mullerian hormone , ovary , rat

References

• Abusief, M.E., Missmer, S.A., Ginsburg, E.S.,2010. Weeks JC, Partridge AH. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer. (4):791-8.
• Al-Azemi, M., Kyrou, D., Kolibianakis, E.M., Humaidan, P., Van Vaerenbergh, I.,Devroey, P., et al., 2012. Elevated progesterone during ovarian stimulation for IVF. Reproductive biomedicine online. 24(4):381-8.
• Bang, K.H., Na, Y.G., 2019. The Delivery Strategy of Paclitaxel Nanostructured Lipid Carrier Coated with Platelet Membrane. 11(6).
• Barad, D., Gleicher, N.,2006. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Human reproduction. 21(11):2845-9.
• Barad, D.H., Weghofer, A., Gleicher, N., 2009. Dehydroepiandrosterone treatment of ovarian failure. Fertility and sterility. 91(5):e14; author reply e5.
• Bernabeu, E,, Gonzalez, L., Cagel, M., Gergic, E.P., Moretton, M.A., Chiappetta, D.A.,2016. Novel Soluplus((R))-TPGS mixed micelles for encapsulation of paclitaxel with enhanced in vitro cytotoxicity on breast and ovarian cancer cell lines. Colloids and surfaces B, Biointerfaces. 140:403-11.
• Bosch, E., Valencia, I., Escudero, E., Crespo, J., Simon, C., Remohi, J., et al.,2003. Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome. Fertility and sterility. 80(6):1444-9.
• Broer, S.L., Dolleman, M., Opmeer, B.C., Fauser, B.C., Mol, B.W., Broekmans, F.J.,2011. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Human reproduction update. 17(1):46-54.
• Celik, O., Turkoz, Y., Hascalik, S., Hascalik, M., Cigremis, Y., Mizrak, B., et al.,2004. The protective effect of caffeic acid phenethyl ester on ischemia-reperfusion injury in rat ovary. European journal of obstetrics, gynecology, and reproductive biology. 117(2):183-8.
• Cheng, R., Xiong, W., Luo, X., Ma, Y., Nie, Y., Qiao, X., et al.,2019. Association of gene polymorphisms in the anti-Mullerian hormone signalling pathway with ovarian function: a systematic review and meta-analysis. Reproductive biomedicine online. 39(3):513-21.
• Davis, A.L., Klitus, M., Mintzer, D.M.,2005. Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of the addition of taxanes. Clinical breast cancer. 6(5):421-4.
• Dwivedi, P., Han, S., Mangrio, F., Fan, R., Dwivedi, M., Zhu, Z., et al.,2019. Engineered multifunctional biodegradable hybrid microparticles for paclitaxel delivery in cancer therapy. Materials science & engineering C, Materials for biological applications. 102:113-23.
• Fornier, M.N., Modi, S., Panageas, K.S., Norton, L., Hudis, C.,2005. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer. 104(8):1575-9.
• Gleicher, N., Barad, D.H.,2008. Androgen priming before ovarian stimulation for IVF. Human reproduction. 23(12):2868-70; author reply 70-1.
• Gucer, F., Balkanli-Kaplan, P., Doganay, L., Yuce, M.A., Demiralay, E., Sayin, N.C., et al.,2001. Effect of paclitaxel on primordial follicular reserve in mice. Fertility and sterility. 76(3):628-9.
• Hassa, H., Aydin, Y., Ozatik, O., Erol, K., Ozatik, Y.,2015. Effects of dehydroepiandrosterone (DHEA) on follicular dynamics in a diminished ovarian reserve in vivo model. Systems biology in reproductive medicine. 61(3):117-21.
• Holden, A., Varcoe, R.L.,2019. Paclitaxel and Mortality: The Dose Argument Is Critical. 26(4):467-70.
• Ili, P., Sari, F., Bucak, M.N., Ozturk, C., Gungor, S., Ataman, M.B.,2019. DNA damaging effect of paclitaxel in the epididymal sperms as a chemotherapeutic agent and possible remedies to prevent this effect: A study on reproductive potential of male cancer patients of reproductive age. Theriogenology. 132:201-11.
• Iliodromiti, S., Nelson, S.M.,2015. Ovarian response biomarkers: physiology and performance. Current opinion in obstetrics & gynecology. 27(3):182-6.
• Jayaprakasan, K., Campbell, B., Hopkisson, J., Johnson, I., Raine-Fenning, N. A.,2010. prospective, comparative analysis of anti-Mullerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. Fertility and sterility. 93(3):855-64.
• Jayaprakasan, K., Narkwichean, A., Maalouf, W.E., Campbell, B.K.,2014. Efficacy of dehydroepiandrosterone to overcome the effect of ovarian ageing (DITTO): a proof of principle randomised controlled trial protocol. BMJ open. 4(10):e005767.
• Klinge, C.M., Clark, B.J., Prough, R.A.,2018 .Dehydroepiandrosterone Research: Past, Current, and Future. Vitamins and hormones. 108:1-28.
• Li, J., Yuan, H., Chen, Y., Wu, H., Wu, H., Li, L,2015. A meta-analysis of dehydroepiandrosterone supplementation among women with diminished ovarian reserve undergoing in vitro fertilization or intracytoplasmic sperm injection. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 131(3):240-5.
• Lyttle S, B., Grover, N., Mesen, T., Steiner, A., Mersereau, J.,2017. Modeling of live-birth rates and cost-effectiveness of oocyte cryopreservation for cancer patients prior to high- and low-risk gonadotoxic chemotherapy. Human reproduction. 32(10):2049-55.
• Massey, A.E., Sikander, M., Chauhan, N., Kumari, S., Setua, S., Shetty, A.B., et al.,2019. Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. Nanomedicine : nanotechnology, biology, and medicine. 20:102027.
• Meirow, D., Dor, J., Kaufman, B., Shrim, A., Rabinovici, J., Schiff, E., et al.,2007. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Human reproduction. 22(6):1626-33.
• Moku, G., Layek, B., 2019. Improving Payload Capacity and Anti-Tumor Efficacy of Mesenchymal Stem Cells Using TAT Peptide Functionalized Polymeric Nanoparticles.11(4).
• Nicosia, S.V., Matus-Ridley ,M., Meadows, A.T.,1985. Gonadal effects of cancer therapy in girls. Cancer. 55(10):2364-72.
• Ozcelik, B., Turkyilmaz, C., Ozgun, M.T., Serin, I.S., Batukan, C., Ozdamar, S., et al.,2010. Prevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin-releasing hormone agonist. Fertility and sterility. 93(5):1609-14.
• Parlakgumus, H.A., Aka, B. F., Bulgan, Kilicdag, E., Simsek, E., Parlakgumus, A.,2014. Atorvastatin for ovarian torsion: effects on follicle counts, AMH, and VEGF expression. European journal of obstetrics, gynecology, and reproductive biology. 175:186-90.
• Siegel, R.L., Miller, K.D., Jemal, A.,2018. Cancer statistics, 68(1):7-30.
• Sonigo, C., Beau, I.,2019. Anti-Mullerian Hormone in Fertility Preservation: Clinical and Therapeutic Applications. 13:1179558119854755.
• Stracquadanio, M., Ciotta, L., Palumbo, M.A,,2018. Relationship between serum anti-Mullerian hormone and intrafollicular AMH levels in PCOS women. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 34(3):223-8.
• Tartagni, M., Cicinelli, M.V., Baldini, D., Tartagni, M.V., 2015. Alrasheed H, DeSalvia MA, et al. Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old. Reproductive biology and endocrinology : RB&E. 13:18.
• Tarumi, W., Suzuki, N., Takahashi, N., Kobayashi, Y., Kiguchi, K., Sato, K., et al.,2009. Ovarian toxicity of paclitaxel and effect on fertility in the rat. The journal of obstetrics and gynaecology research.35(3):414-20.
• Tsui, K.H., Lin, L.T., Chang, R., Huang, B.S., Cheng, J.T., Wang, P.H.,2015. Effects of dehydroepiandrosterone supplementation on women with poor ovarian response: A preliminary report and review. Taiwanese journal of obstetrics & gynecology. 54(2):131-6.
• Tsui, K.H., Lin, L.T., Horng, H.C., Chang, R., Huang, B.S., Cheng, J.T., et al.,2014. Gene expression of cumulus cells in women with poor ovarian response after dehydroepiandrosterone supplementation. Taiwanese journal of obstetrics & gynecology. 53(4):559-65.
• Ubaldi, F., Albano, C., Peukert, M., Riethmuller-Winzen, H., Camus, M., Smitz, J., et al.,1996. Subtle progesterone rise after the administration of the gonadotrophin-releasing hormone antagonist cetrorelix in intracytoplasmic sperm injection cycles. Human reproduction. 11(7):1405-7.
• Wang, T.H., Wang, H.S., Soong, Y.K.,2000. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer.88(11):2619-28.
• Wang, Y.X., Zhu, W.J., Xie, B.G.,2014. Expression of PPAR-gamma in adipose tissue of rats with polycystic ovary syndrome induced by DHEA. Molecular medicine reports. 9(3):889-93.
• Wani, MC., Taylor, H.L., Wall, M.E., Coggon, P., McPhail, A.T.,1971. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. Journal of the American Chemical Society. 93(9):2325-7.
• Yeung, T.W., Chai, J., Li, R.H., Lee, V.C., Ho, P.C., Ng, E.H., 2014. A randomized, controlled, pilot trial on the effect of dehydroepiandrosterone on ovarian response markers, ovarian response, and in vitro fertilization outcomes in poor responders. Fertility and sterility. 102(1):108-15.e1.
• Yucebilgin, M.S., Terek, M.C., Ozsaran, A., Akercan, F., Zekioglu, O., Isik, E., et al.,2004. Effect of chemotherapy on primordial follicular reserve of rat: an animal model of premature ovarian failure and infertility. The Australian & New Zealand journal of obstetrics & gynaecology. 44(1):6-9.
• Zajdel, A., Wilczok, A., 2019. Cytotoxic Effect of Paclitaxel and Lapatinib Co-Delivered in Polylactide-co-Poly(ethylene glycol) Micelles on HER-2-Negative Breast Cancer Cells.11(4).
• Zhang, H.H., Xu, P.Y., Wu, J., Zou, W.W., Xu, X.M., Cao, X.Y., et al.,2014. Dehydroepiandrosterone improves follicular fluid bone morphogenetic protein-15 and accumulated embryo score of infertility patients with diminished ovarian reserve undergoing in vitro fertilization: a randomized controlled trial. Journal of ovarian research. 7:93.
• Zhu, L., Chen, L.,2019. Progress in research on paclitaxel and tumor immunotherapy. 24:40.